Nuon Therapeutics, Inc.

Nuon Therapeutics To Present At Biopartnering Europe

San Mateo, CA, October 12, 2009 – Nuon Therapeutics, Inc., a clinical stage, privately-held biopharmaceutical company focused on novel therapies for autoimmune and inflammatory diseases, announced today that Paulette Dillon, chief business officer, will present at the BioPartnering Europe Conference in London, UK. Ms. Dillon will provide a corporate overview, including an update on the company’s progress with its lead product candidate, tranilast, which is in Phase 2 clinical development for several indications including rheumatoid arthritis. The presentation will be given on Tuesday, October 13, 2009, at 2:30 pm [14:30 UTC], in the QEII Conference Centre.

“Participation in this well-attended global conference allows us to showcase our streamlined development pathway for tranilast,” said Ms. Dillon. “It also provides an excellent opportunity to meet with potential commercial partners and identify new in-licensing opportunities.”

About Nuon Therapeutics, Inc.

Nuon Therapeutics, Inc. is a clinical stage biopharmaceutical company that develops innovative small molecule drugs that address critical, unmet needs in autoimmune and inflammatory diseases. The Company has raised a total of $32 million since 2006 from investors including Domain Associates, L.L.C., Frazier Healthcare Ventures, and GBS Venture Partners. Nuon Therapeutics, Inc. has its headquarters in San Mateo, CA. For additional information, please visit: www.nuontherapeutics.com

Contact: